看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
. A% K6 @, s& h4 J: Q# k8 t% D4 i+ Z; f6 X
, J3 V8 }0 }8 H& O4 l
Currently available feasibility data for possible combination strategies.
) s% A6 r7 n$ I7 |————————————————————————————————
3 `- G; N8 M4 D& VCombination Feasibility according to preliminary data - O; s( m$ u& D3 v
——————————————————————————————————# m0 u/ o, \3 @$ s
Bevacizumab + sorafenib Yes, reduced dose
% A6 D+ J) a8 J$ LBevacizumab + sunitinib† No
: [: L; K u( P. K0 {Bevacizumab + temsirolimus Yes * [1 M) ~+ Z; X9 H
Bevacizumab + everolimus Yes % n+ g* H; B9 k- L# v) N3 U3 F1 }. d
Sorafenib + sunitinib ? 1 t/ d4 t n3 |
Sorafenib + temsirolimus Yes, reduced dose
& w K% q/ Q$ `2 @& V! Q1 uSorafenib + everolimus Yes, reduced dose : c* T- o7 o2 s' d. _, ^
Sunitinib + temsirolimus† No " @) i. [% |, A9 [
Sunitinib + everolimus ? ' G1 o P2 E a8 @1 P
Temsirolimus + everolimus ? / K7 n/ Q; T9 k: e
————————————————————
& M0 q, V/ F: P& W0 H†Led to US FDA warning.) ?0 W, _; c9 v4 U9 w( L% @
?: As yet unattempted combination.9 i$ k* `6 z4 J$ Y
|
显身卡
' o2 K0 ~' o* {* I; `5 }. H5 L8 K
